A coalition of Christian investors managing over $4 billion in assets has filed 38 shareholder proposals for 2026, urging major corporations to abandon politically charged social initiatives and refocus on core business operations and fiduciary duties.
Apeiron Capital Ltd. has liquidated its entire position in the iShares Ethereum Trust ETF, a move highlighting shifting institutional sentiment as digital asset volatility persists.
A discounted cash flow analysis suggests L.B. Foster Company's shares may be trading at a substantial discount to their intrinsic value, presenting a potential opportunity for investors.
In a parliamentary submission, the crypto exchange alleges major Australian banks are unlawfully cutting off services to legitimate digital asset firms, creating a 'crisis of confidence' and stifling innovation as the country moves to formalize crypto regulation.
The explosive demand for AI is triggering a seismic shift in commercial real estate, as investors pour capital into specialized data centers designed to handle the immense power and cooling needs of next-generation computing.
India's Supreme Court has issued a stern warning to Meta's WhatsApp, questioning its data monetization and user consent model in a market where the app holds a dominant position. The court has temporarily barred data sharing pending a detailed examination.
As the TSX rides a wave of robust Q4 earnings, savvy investors are looking past the blue chips. We delve into three lesser-known Canadian companies—spanning energy, aerospace, and energy services—that combine solid fundamentals with strategic moves to capitalize on current economic tailwinds.
Pfizer reported fourth-quarter revenue and profit that topped Wall Street forecasts, yet year-over-year sales dipped slightly. The pharmaceutical giant's results highlight the ongoing challenge of moving beyond its COVID-19 windfall.
Packaging giant Ball Corporation (NYSE: BALL) delivered a robust fourth-quarter performance for 2025, surpassing revenue and profit expectations. The company's focus on operational discipline and shareholder returns, including $1.54 billion in buybacks and dividends, capped a record year.
Elon Musk forecasts China's electricity generation will outpace the United States by a factor of three within the next few years, citing the nation's breakneck expansion in solar and grid infrastructure as a pivotal shift in global energy leadership.
Despite a robust 45% surge in earnings per share, Lonza Group AG (VTX:LONN) shareholders have seen their investment decline by 11% over the past year, starkly underperforming the broader Swiss market. This divergence underscores how investor sentiment and future expectations can overshadow even solid current financial performance.
GE HealthCare secures dual US and European regulatory approvals for its new Allia Moveo imaging system, designed to enhance patient comfort and streamline clinical workflows in minimally invasive procedures.
Despite a recent $1.5 billion capital raise sparking acquisition speculation, SoFi's leadership indicates a disciplined approach to deals, prioritizing organic growth and strategic product expansion over costly buyouts.
The prominent value investment firm has initiated a significant new position in UniFirst, a uniform and facility services provider, signaling confidence in its recurring revenue model despite recent stock underperformance.
Amazon Web Services warns that multi-year delays in securing power grid connections are jeopardizing its data center investments across Europe, highlighting a critical infrastructure bottleneck for the continent's digital and industrial ambitions.
CNBC's Jim Cramer highlights Reddit (NYSE: RDDT) in his latest market strategy, pointing to its extreme price swings and speculating on a near-term rise. The social media platform's stock continues to draw attention for its reactive trading patterns.
CNBC's Jim Cramer expresses strong confidence in Affirm Holdings ahead of its earnings, crediting CEO Max Levchin's leadership for potentially outperforming market expectations and challenging bearish sentiment.
After years of losses, Evolent Health has broken into profitability with a rising capital base. While its Return on Capital Employed (ROCE) remains low, the accelerating trend suggests a potential inflection point for the healthcare services firm.
Pfizer's shares have staged a notable rebound in recent months, drawing investor attention as the company pivots towards oncology. We examine whether the current valuation reflects its long-term growth potential or lingering post-pandemic challenges.
Aquestive Therapeutics faces a regulatory delay for its sublingual epinephrine film, Anaphylm, after the FDA raised concerns primarily about its packaging and labeling. The company views the issues as solvable and is moving forward with redesigns and new studies, aiming for a 2026 resubmission while advancing parallel filings abroad.
